Scarica l'app Stockscreener
1.90
3.83%
0.07
Dopo l'orario di chiusura:
1.87
-0.03
-1.58%
Precedente Chiudi:
$1.83
Aprire:
$1.83
Volume 24 ore:
311.24K
Relative Volume:
0.21
Capitalizzazione di mercato:
$53.17M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-0.3072
EPS:
-6.1852
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
+6.15%
1M Prestazione:
+11.11%
6M Prestazione:
-71.94%
1 anno Prestazione:
-90.90%
Intervallo 1D:
$1.83
$1.92
Intervallo di 1 settimana:
$1.76
$1.92
Portata 52W:
$1.39
$21.27
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Confronta JSPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.90 | 51.21M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
What analysts say about Jasper Therapeutics Inc stockTop Performing Stocks & Low Risk Trading Alerts - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
2025-12-28 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Earnings Notes - Trefis
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
Evercore ISI Remains a Buy on Jasper Therapeutics (JSPR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect - ACCESS Newswire
2025-12-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Connect - ACCESS Newswire
Penny Stocks To Watch NowDecember 2nd - MarketBeat
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper’s Stock Is In The Basement, But The Bet Is Binary - Finimize
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Reports Positive Phase 1b Study Results - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR) - The Globe and Mail
Jasper Therapeutics stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Jasper Therapeutics’ Briquilimab Program Shines Amid Financial Losses - StocksToTrade
Jasper Therapeutics, Inc. (JSPR) Stock: Surges as New Asthma Trial Data Shows Promising Results - parameter.io
Jasper Therapeutics’ Briquilimab: Stepping Up? - StocksToTrade
Can Jasper Therapeutics Deliver on New Studies? - timothysykes.com
$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Anticipates Growth with Briquilimab Highlights - timothysykes.com
Why Is Jasper Therapeutics Stock Surging Tuesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Can Jasper Therapeutics’ Progress Propel Its Stock? - timothysykes.com
JSPR Explodes on Briquilimab Asthma Breakthrough - RagingBull
Jasper stock jumps after positive asthma study results - Investing.com India
Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study - Nasdaq
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - Sahm
Jasper Therapeutics Reports Positive Data from ETESIAN Study and BEACON Investigation - TradingView
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in ... - Enidnews.com
Jasper Stock Jumps After Promising New Asthma Study Results - Sahm
Jasper Therapeutics To Host Webinar To Present BEACON And ETESIAN Study Results - Nasdaq
Jasper Therapeutics to Host an Investor Webinar on December - GlobeNewswire
Jasper Therapeutics (Nasdaq: JSPR) to host Dec. 2 webinar on ETESIAN, BEACON studies - Stock Titan
JSPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ROSEN, REGARDED INVESTOR COUNSEL, Encourages Jasper Therapeutics - The National Law Review
Jasper Therapeutics Inc. (JSPR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages - Defense World
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Yahoo Finance
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):